| Wall Street Analysts Believe Kamada (KMDA) Could Rally 106.56%: Here's is How to Trade |
The mean of analysts' price targets for Kamada (KMDA) points to a 106.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-05-16 15:01:11 |
Czytaj oryginał (ang.) |
| Kamada Ltd. (KMDA) Q1 2025 Earnings Call Transcript |
Start Time: 08:30 January 1, 0000 8:53 AM ET Kamada Ltd. (NASDAQ:KMDA ) Q1 2025 Earnings Conference Call May 14, 2025, 08:30 AM ET Company Participants Amir London - CEO Chaime Orlev - CFO Brian Ritchie - LifeSci Advisors Conference Call Participants Annabel Samimy - Stifel James Sidoti - Sidoti & Company Operator Greetings, and welcome to the Kamada First Quarter 2025 Earnings Conference Call. |
seekingalpha.com |
2025-05-14 17:48:01 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Kamada (KMDA) Q1 Earnings: A Look at Key Metrics |
While the top- and bottom-line numbers for Kamada (KMDA) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-05-14 14:30:44 |
Czytaj oryginał (ang.) |
| Kamada (KMDA) Q1 Earnings Match Estimates |
Kamada (KMDA) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.04 per share a year ago. |
zacks.com |
2025-05-14 13:10:40 |
Czytaj oryginał (ang.) |
| Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability |
REHOVOT, Israel and HOBOKEN, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the three months ended March 31, 2025. |
globenewswire.com |
2025-05-14 11:00:00 |
Czytaj oryginał (ang.) |
| Kamada (KMDA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates |
Besides Wall Street's top -and-bottom-line estimates for Kamada (KMDA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025. |
zacks.com |
2025-05-09 14:20:43 |
Czytaj oryginał (ang.) |
| Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas |
REHOVOT, Israel and HOBOKEN, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced the expansion of its plasma collection operations with the opening of a third plasma collection center. The new 11,100 square foot center in San Antonio, TX, is operated by Kamada's wholly owned subsidiary, Kamada Plasma, and is planned to support close to 50 donor beds with an estimated total collection capacity of approximately 50,000 liters annually. |
globenewswire.com |
2025-03-19 09:00:00 |
Czytaj oryginał (ang.) |
| Kamada Ltd. (KMDA) Q4 2024 Earnings Call Transcript |
Kamada Ltd. (NASDAQ:KMDA ) Q4 2024 Earnings Conference Call March 5, 2025 8:00 AM ET Company Participants Brian Ritchie – LifeSci Advisors Amir London – Chief Executive Officer Chaime Orlev – Chief Financial Officer Conference Call Participants Annabel Samimy – Stifel Anthony Petrone – Mizuho Group James Sidoti – Sidoti & Co. Operator Greetings, and welcome to the Kamada Fourth Quarter and Full Year 2024 Earnings Conference Call. |
seekingalpha.com |
2025-03-05 13:06:43 |
Czytaj oryginał (ang.) |
| Kamada Reports Record Top and Bottom Line 2024 Financial Results and Affirms 2025 Guidance Representing Double-Digit Profitable Growth |
REHOVOT, Israel, and HOBOKEN, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the three months and year ended December 31, 2024. |
globenewswire.com |
2025-03-05 09:05:00 |
Czytaj oryginał (ang.) |
| Kamada to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 5, 2025 |
REHOVOT, Israel, and HOBOKEN, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. |
globenewswire.com |
2025-02-26 09:00:00 |
Czytaj oryginał (ang.) |
| Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America |
REHOVOT, Israel and HOBOKEN, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it was awarded a contract with an international organization for the supply of KAMRAB® and VARIZIG® in Latin America for 2025-2027. Total expected revenue under the three-year contract for both products is estimated to be approximately $25 million. The expected portion for the calendar year 2025 is incorporated into the Company's recently announced 2025 revenue guidance. |
globenewswire.com |
2025-01-22 09:00:00 |
Czytaj oryginał (ang.) |
| Kamada Ltd. (KMDA) Q3 2024 Earnings Call Transcript |
Call Start: 08:30 January 1, 0000 9:52 AM ET Kamada Ltd. (NASDAQ:KMDA ) Q3 2024 Earnings Conference Call November 13, 2024, 08:30 AM ET Company Participants Brian Ritchie - LifeSci Advisors Amir London - Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Operator Greetings, and welcome to the Kamada Ltd. |
seekingalpha.com |
2024-11-13 11:54:29 |
Czytaj oryginał (ang.) |
| Kamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in Houston |
REHOVOT, Israel and HOBOKEN, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced the expansion of its plasma collection operations with the opening of a new plasma collection center in Houston, TX. The new 12,000 square foot center is operated by Kamada's wholly owned subsidiary, Kamada Plasma, and is planned to support over 50 donor beds with an estimated total collection capacity of approximately 50,000 liters annually. |
globenewswire.com |
2024-09-23 11:00:00 |
Czytaj oryginał (ang.) |
| Kamada Ltd. (KMDA) Q2 2024 Earnings Call Transcript |
Kamada Ltd. (NASDAQ:KMDA ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Troy Williams - LifeSci Advisors Amir London - Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Operator Greetings, and welcome to Kamada Limited Second Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-08-14 17:45:27 |
Czytaj oryginał (ang.) |
| Kamada to Announce Second Quarter and First Half Ended June 30, 2024 Financial Results and Host Conference Call on August 14, 2024 |
REHOVOT, Israel, and HOBOKEN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the second quarter and first half ended June 30, 2024, prior to the open of the U.S. financial markets on Wednesday, August 14, 2024. |
globenewswire.com |
2024-08-07 11:00:00 |
Czytaj oryginał (ang.) |
| 3 Promising Biotech Stocks You Can Pick Up for Less Than $10 |
What could be better than viable enterprises within the biotechnology industry? Try biotech stocks under $10. |
investorplace.com |
2024-07-29 19:04:34 |
Czytaj oryginał (ang.) |
| Kamada Ltd. (KMDA) Q1 2024 Earnings Call Transcript |
Kamada Ltd. (NASDAQ:KMDA ) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors, LLC Amir London - Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Operator Good morning, ladies and gentlemen, and welcome to the Kamada Limited First Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-05-08 15:55:04 |
Czytaj oryginał (ang.) |
| Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance |
REHOVOT, Israel and HOBOKEN, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for three months ended March 31, 2024. |
globenewswire.com |
2024-05-08 11:00:00 |
Czytaj oryginał (ang.) |
| Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 |
REHOVOT, Israel and HOBOKEN, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter ended March 31, 2024, prior to the open of the U.S. financial markets on Wednesday, May 8, 2024. |
globenewswire.com |
2024-05-01 11:00:00 |
Czytaj oryginał (ang.) |
| Kamada Ltd. (KMDA) Q4 2023 Earnings Call Transcript |
Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Results Earnings Conference Call March 6, 2024 8:30 AM ET |
seekingalpha.com |
2024-03-06 16:22:00 |
Czytaj oryginał (ang.) |
| Kamada Issues 2024 CEO Letter to Shareholders |
REHOVOT, Israel, and HOBOKEN, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today issued a Letter to Shareholders from Amir London, Chief Executive Officer. |
globenewswire.com |
2024-03-06 09:05:00 |
Czytaj oryginał (ang.) |
| Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability |
REHOVOT, Israel, and HOBOKEN, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the three months and year ended December 31, 2023. |
globenewswire.com |
2024-03-06 09:00:00 |
Czytaj oryginał (ang.) |
| Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024 |
REHOVOT, Israel, and HOBOKEN, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. |
globenewswire.com |
2024-02-28 09:00:00 |
Czytaj oryginał (ang.) |
| Kamada: Kedrion Deal Locks In Growth |
Kamada is a profitable specialty plasma company with a strong balance sheet and significant capital available for investment. The company has announced an expanded commercial agreement for its anti-rabies drug Kedrab including a minimum revenue guarantee for the next four years. The new deal significantly derisks the Kamada investment case by locking in growth for one of the company's largest revenue streams. |
seekingalpha.com |
2023-12-08 20:42:29 |
Czytaj oryginał (ang.) |
| KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB® |
Since 2018 Kedrion has had exclusive distribution rights in the US for KEDRAB®, a Human Rabies Immune Globulin (HRIG) developed in partnership with Kamada Ltd. New agreement becomes effective in January 2024 and includes potential expansion of Kedrion's distribution of KEDRAB® in additional territories beyond the US Rabies is a global public health concern that is responsible for more than 59,000 human deaths per year in the world; an estimated 60,000 Americans receive Rabies post exposure prophylaxis each year Kedrion confirms its commitment to fighting Rabies and other serious and life-threatening diseases and conditions CASTELVECCHIO PASCOLI, Italy , Dec. 7, 2023 /PRNewswire/ -- Kedrion Biopharma , a leading global biopharmaceutical company that develops, manufactures and commercializes therapeutic products derived from blood plasma , announces the execution of a binding memorandum of understanding with Kamada Ltd. |
prnewswire.com |
2023-12-07 13:00:00 |
Czytaj oryginał (ang.) |
| Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years |
REHOVOT, Israel and HOBOKEN, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced the execution of a binding memorandum of understanding with Kedrion for the amendment and extension of the KEDRAB® U.S. distribution agreement between the parties. Within the first four years of the eight-year term, which begins in January 2024, Kedrion will purchase minimum quantities of KEDRAB with revenues to Kamada of approximately $180 million. |
globenewswire.com |
2023-12-06 09:00:00 |
Czytaj oryginał (ang.) |
| Celebrating Seeking Alpha's New Analysts - November 2023 Edition |
In November, we welcomed 24 new analysts who published their first article on Seeking Alpha. This series highlights and welcomes these newcomers to our ranks of analysts who share their unique insights and perspectives as well as some of their top investing ideas. We've compiled all of their firsts here for your review and to showcase the new perspectives being offered on the platform. |
seekingalpha.com |
2023-12-05 14:00:00 |
Czytaj oryginał (ang.) |
| Kamada: Solid Specialty Plasma Play |
Kamada is a profitable specialty plasma company with a strong balance sheet and significant capital available for investment. The company is expected to grow EBITDA significantly in the coming years through its existing business and potential acquisitions or licensing of new products. Limited downside outside Israel country risk. |
seekingalpha.com |
2023-11-21 12:11:25 |
Czytaj oryginał (ang.) |
| Kamada Ltd. (KMDA) Q3 2023 Earnings Call Transcript |
Kamada Ltd. (NASDAQ:KMDA ) Q3 2023 Earnings Conference Call November 13, 2023 8:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Operator Good day ladies and gentlemen and welcome to Kamada Ltd. |
seekingalpha.com |
2023-11-13 13:08:06 |
Czytaj oryginał (ang.) |
| Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance |
REHOVOT, Israel and HOBOKEN, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the three and nine months ended September 30, 2023. |
globenewswire.com |
2023-11-13 09:00:00 |
Czytaj oryginał (ang.) |
| Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023 |
REHOVOT, Israel, and HOBOKEN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and first nine months ended September 30, 2023, prior to the open of the U.S. financial markets on Monday, November 13, 2023. |
globenewswire.com |
2023-11-08 09:00:00 |
Czytaj oryginał (ang.) |